share_log

Earnings Troubles May Signal Larger Issues for LanZhou Foci PharmaceuticalLtd (SZSE:002644) Shareholders

Earnings Troubles May Signal Larger Issues for LanZhou Foci PharmaceuticalLtd (SZSE:002644) Shareholders

盈利问题可能预示着兰州福成药业股份有限公司(SZSE:002644)股东面临更大的问题
Simply Wall St ·  09/02 02:53

The subdued market reaction suggests that LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) recent earnings didn't contain any surprises. We think that investors are worried about some weaknesses underlying the earnings.

市场反应平淡,这表明佛慈制药最近的收益没有带来任何惊喜。我们认为投资者对收益背后的一些弱点感到担忧。

big
SZSE:002644 Earnings and Revenue History September 2nd 2024
SZSE:002644的盈利和营业收入历史 2024年9月2日

The Impact Of Unusual Items On Profit

除了稀释之外,还应该注意的是,万集科技在过去12个月中因不寻常项目获得了价值人民币3.5万元的利润。虽然我们希望看到利润增加,但当这些不寻常项目对利润做出重大贡献时,我们会更加谨慎。我们对全球大部分上市公司的数据进行了分析,发现不寻常项目往往是一次性的。这正如我们所期望的那样,因为这些提升被描述为"不寻常"。相对于其利润而言,万集科技在2021年12月前的不寻常项目贡献大。因此,我们可以推断出,这些不寻常项目正在使其财务利润显著增强。

For anyone who wants to understand LanZhou Foci PharmaceuticalLtd's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥7.0m worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And that's as you'd expect, given these boosts are described as 'unusual'. If LanZhou Foci PharmaceuticalLtd doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

对于想要了解佛慈制药除了法定数字之外的利润的人来说,重要的是要注意,在过去的十二个月里,法定利润中从价值为700万人民币的非凡项目获得的利润。尽管获得更高的利润总是令人愉快的,但非凡项目的大额贡献有时会减少我们的热情。当我们对成千上万上市公司进行数据分析时,我们发现,一个年度中非凡项目的推动通常在下一年不会重复。这也是可以理解的,毕竟这些推动被描述为“非凡”。如果佛慈制药在未来的年份里没有看到这种贡献重复,那么其他条件相等的情况下,我们预计其利润将在当前年份下降。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of LanZhou Foci PharmaceuticalLtd.

注意:我们始终建议投资者检查资产负债表的实力。点击这里查看我们对佛慈制药的资产负债表分析。

Our Take On LanZhou Foci PharmaceuticalLtd's Profit Performance

我们对佛慈制药的利润表现的看法

We'd posit that LanZhou Foci PharmaceuticalLtd's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Therefore, it seems possible to us that LanZhou Foci PharmaceuticalLtd's true underlying earnings power is actually less than its statutory profit. In further bad news, its earnings per share decreased in the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you want to do dive deeper into LanZhou Foci PharmaceuticalLtd, you'd also look into what risks it is currently facing. For example, LanZhou Foci PharmaceuticalLtd has 2 warning signs (and 1 which doesn't sit too well with us) we think you should know about.

我们认为,由于存在大额飞凡项目,佛慈制药的法定收益并不能清晰反映当前的生产力。因此,我们认为,佛慈制药的真实基本收益能力实际上低于其法定利润。更糟糕的是,其每股收益在过去一年有所下降。当然,在分析其收益时,我们只是触及了表面;人们还可以考虑利润率、预测增长和投资回报等其他因素。如果你想深入研究佛慈制药,你还需要了解它当前面临的风险。例如,佛慈制药有2个警示信号(以及1个我们认为不太好的信号),我们认为你应该知道。

This note has only looked at a single factor that sheds light on the nature of LanZhou Foci PharmaceuticalLtd's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

本文仅考虑了一个揭示佛慈制药利润本质的因素。但有许多其他方法可以了解一家公司。例如,许多人认为高净资产收益率是有利的商业经济指标,而其他人则喜欢“追踪资金”,寻找内部人员正在购买的股票。尽管这可能需要你进行一些研究,但你可能会发现这个免费的高净资产收益率公司收藏或者拥有重要内部人持股的股票清单很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发